AKT1 and postmenopausal osteoporosis: In rats with OVX-induced postmenopausal osteoporosis, QEP reduced ferroptosis and increased the activation of the Protein Kinase B/Phosphoinositide 3-Kinase (AKT/PI3K) pathway to promote osteoblast development and prevent bone loss; thus, QEP is a potential drug for treating OP [180].